

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adam Blumenthal
Date of last notice	8 July 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none"> - Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C> - Atlantic Capital Holdings Pty <Atlantic Capital A/C> <p>Both of the above entities are director-related entities.</p>
Date of change	11 February 2020 & 12 February 2020
No. of securities held prior to change	<p><u>Direct:</u></p> <p>Adam Blumenthal:</p> <ul style="list-style-type: none"> - 1 Fully Paid Ordinary Share <p><u>Indirect:</u></p> <p>Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>:</p> <ul style="list-style-type: none"> - 6,250,000 Fully Paid Ordinary Shares - 2,750,000 Listed CPHO Options (\$0.80, 21 August 2020)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	<ul style="list-style-type: none"> - Fully Paid Ordinary Shares - CPHOPT20 Options (\$0.35, 12 Feb 2023)
Number acquired	<ul style="list-style-type: none"> - 1,958,387 Fully Paid Ordinary Shares - 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023)
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p><u>Direct:</u></p> <p>Adam Blumenthal:</p> <ul style="list-style-type: none"> - 1 Fully Paid Ordinary Share <p><u>Indirect:</u></p> <p>Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>:</p> <ul style="list-style-type: none"> - 6,250,000 Fully Paid Ordinary Shares - 2,750,000 Listed CPHO Options (\$0.80, 21 August 2020) <p>Atlantic Capital Holdings Pty <Atlantic Capital A/C>:</p> <ul style="list-style-type: none"> - 1,958,387 Fully Paid Ordinary Shares - 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Atlantic Capital Holdings Pty <Atlantic Capital A/C>, as nominee for EverBlu Capital Pty Ltd ("Everblu"), received 1,958,387 Ordinary Shares and 2,128,387 Options as a part allocation for services provided by Everblu in respect of the Tranche 1 Convertible Notes, Tranche 2 Convertible Notes and Placement.</p> <p>Refer to the Prospectus dated 7 February 2020 for further details.</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.